Pharmacokinetic-pharmacodynamic study of itraconazole in patients with fungal infections in intensive care units

Journal of Infection and Chemotherapy

Volumn 17, Issue 2, 2011, Pages 224-230

  Hagihara, Mao ^a   Kasai, Hidefumi ^c   Umemura, Takumi ^b   Kato, Takahiro ^a   Hasegawa, Takaaki ^a   Mikamo, Hiroshige ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MEIJO UNIVERSITY   (Japan)

^c Clinical Pharmacology Group   (Japan)

Author keywords

Candida; Itraconazole; Pharmacokinetics pharmacodynamics (PK PD)

Indexed keywords

AMIKACIN; CIPROFLOXACIN; CLINDAMYCIN; DORIPENEM; IMIPENEM; ITRACONAZOLE; LINEZOLID; MEROPENEM; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIFUNGAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ARTICLE; CANDIDA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; JAPAN; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; PHARMACODYNAMICS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 79955902959     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-010-0102-4     Document Type: Article

References (31)

1. Link H, Bohme A, Cornely OA, Höffken K, Kellner O, Kern WV, Mahlberg R, Maschmeyer G, Nowrousian MR, Ostermann H, Ruhnke M, Sezer O, Schiel X, Wilhelm M, Auner HW. Antimicrobial therapy of unexplained fever in neutropenic patients - guidelines of the Infectious Disease Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol. 2003;82(Suppl 2):S105-17.
2. Klastersky J. Empirical antifungal therapy. Int J Antimicrob Agents. 2004;23:105-12. (Pubitemid 38175390)
3. Jun HX, Zhixiang S, Chun W, Reksodiputro AH, Ranuhardy D, Tamura K, Matsumoto T, Lee DG, Purushotaman SV, Lim V, Ahmed A, Hussain Y, Chua M, Ong A, Liu CY, Hsueh PR, Lin SF, Liu YC, Suwangool P, Jootar S, Picazo JJ. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever. Int J Antimicrob Agents. 2005;26(Suppl 2): S128-32.
4. Maertens J, Boogaerts M. The place for itraconazole in treatment. J Antimicrob Chemother. 2005;56(Suppl 1):i33-8.
5. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38:161-89. (Pubitemid 38113025)
6. Eggimann P, Garbino J, Pittet D. Management of Candida sepsis infections in critically ill patients. Lancet Infect Dis. 2003;3:772-85. (Pubitemid 37489961)
7. Vincent JL, Anaissie E, Bruining H, Demajo W, el-Ebiary M, Haber J, Hiramatsu Y, Nitenberg G, Nystrom PO, Pittet D, Rogers T, Sandven P, Sganga G, Schaller MD, Solomkin J. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med. 1998;24:206-16.
8. Buchner T, Fegeler W, Bernhardt H, Brockmeyer N, Duswald KH, Herrmann M, Heuser D, Jehn U, Just-Nubling G, Karthaus M, Maschmeyer G, Müller FM, Müller J, Ritter J, Roos N, Ruhnke M, Schmalreck A, Schwarze R, Schwesinger G, Silling G. Treatment of severe Candida infections in high-risk patients in Germany: consensus formed by a panel of interdisciplinary investigators. Eur J Clin Microbiol Infect Dis. 2002;21:337-52. (Pubitemid 34811966)
9. Dimopoulos G, Karabinis A, Samonis G, Falagas ME. Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study. Eur J Clin Microb Infect Dis. 2007;26:377-84. (Pubitemid 46873003)
10. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med. 1989;149:2349-53.
11. Blumberg HM, Jarvis WR, Soucie JM, Edwars JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP. Risk factors for Candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis. 2001;33:177-86.
12. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microb Rev. 2007;20:133-63. (Pubitemid 46167771)
13. Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, Rinaldi MG, Stevens DA, Graybill JR. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000;79:250-60.
14. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358-66. (Pubitemid 32173620)
15. Wingard JR. Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis. 2004;39(Suppl 1):S38-43.
16. Hostetler JS, Heykants J, Clemons KV, Woestenborghs R, Hanson LH, Stevens DA. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. Antimicrob Agents Chemother. 1993;37:2224-7. (Pubitemid 23298215)
17. Odds FC, Bossche HV. Antifungal activity of itraconazole compared with hydroxyl-itraconazole in vitro. J Antimicrob Chemother. 2000;45:371-3. (Pubitemid 30139249)
18. Glasmacher A, Hahn C, Leutner C, Molitor E, Wardelmann E, Losem C, Sauerbruch T, Marklein G, Schmidt-Wolf IG. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses. 1999;42:443-51. (Pubitemid 29470385)
19. Glasmacher A, Hahn C, Molitor E, Marklein G, Sauerbruch T, Schmidt-Wolf IG. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses. 1999;42:591-600. (Pubitemid 30053362)
20. David A. In vivo pharmacodynamics of antifungal drugs in treatment of Candidiasis. Antimicrob Agents Chemother. 2003;47:1179-86.
21. Burggess DS, Hastings RW. A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology. Diagn Microbil Infect Dis. 2000;38:87-93.
22. Manavathu EK, Cutright JL, Chandrasekar PH. Organismdependent fungicidal activities of azoles. Antimicrob Agents Chemother. 1998;42:3018-21.
23. Schafer-Korting M, Korting HC, Amann F, Peuser R, Lukacs A. Influence of albumin on itraconazole and ketoconazole antifungal activity: results of a dynamic in vitro study. Antimicrob Agents Chemother. 1991;35:2053-6.
24. Schafer-Korting M, Korting HC, Ritter W, Obermuller W. Influence of serum protein binding on the in vitro activity of antifungal agents. Infection. 1995;23:292-7.
25. Zhanel GG, Saunders DG, Hoban DJ, Karlowsky JA. Influence of human serum on antifungal pharmacodynamics with Candida albicans. Antimicrob Agents Chemother. 2001;45:2018-22.
26. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother. 2003;47:3165-9.
27. Andes D, van Ogtrop KM. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother. 1999;43:2116-20. (Pubitemid 29421186)
28. Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, Novitzky N, Boehme A, Chwetzoff E, De Beule K. Intravenous and oral itraconazole versus intravenous amphotericin B dexycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med. 2001;135:412-22.
29. Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother. 2005;56(Suppl 1):i17-22.
30. Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, Woestenborghs R, Van Cutsem J, Cauwenbergh G. The clinical pharmacokinetics of itraconazole: an overview. Mycoses. 1989;32(Suppl 1):67-87.
31. Okuda T, Watanabe N, Okuda A, Takao M, Takayanagi K. Monitoring the plasma level of itraconazole administration for prevention of fungal infection: the relationship between the plasma itraconazole level and several clinical parameters. Jpn J TDM. 2008;25:8-12.